Choose a language and wait for the translated text.
Shots:
The US FDA has extended the review period of Belite Bioβs NDA for tinlarebant to treat Stargardt disease type 1 (STGD1) by 3mos., with the new PDUFA action date set as May 12, 2027, to allow additional time to review information submitted in support of the NDA
If no major deficiencies are identified during the ongoing review, the FDA plans to communicate proposed labeling & any anticipated postmarketing requirement requests by Apr 12, 2027
Tinlarebant is an oral therapy that lowers serum RBP4 to reduce bisretinoid formation in the eye; it completed the P-III DRAGON trial in STGD1, which met its 1EP, and is being evaluated in the P-II/III DRAGON II (STGD1) & P-III PHOENIX (GA) trials. It holds the US BTD, FTD & RPDD, ODD in the US, EU, Japan & Switzerland and Sakigake designation in Japan for STGD1
Ref: GlobeNewswire | Image: Belite Bio | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Belite Bio Reports Three-Month Extension of the US FDA Review of Tinlarebant NDA for Stargardt Disease Type 1 appeared first on PharmaShots.